DiaKine Therapeutics, Inc. and Kinexum Metabolics, Inc. to Develop Novel Combination Treatment to Type 1 Diabetes
CHARLOTTESVILLE, Va. & HARPER'S FERRY, W. Va.--(BUSINESS WIRE)--DiaKine Therapeutics, Inc. and Kinexum Metabolics, Inc. today announced an agreement to jointly develop a new combination therapy that has shown, in preclinical studies, to cause type 1 diabetes to go into remission by protecting and promoting the growth of new insulin-producing cells.